Recent Company News

• 09:09 AM ET Oct 29, 2025
  

  Transcript Intelligence: Amarin Corp. Q3 Earnings Guidance ($18.94, 0.00)

• 09:08 AM ET Oct 29, 2025
  

  Transcript Intelligence: Amarin Corp. Q3 Earnings Themes ($18.94, 0.00)

• 09:08 AM ET Oct 29, 2025
  

  Transcript Intelligence: Amarin Corp. Q3 Earnings Q&A ($18.94, 0.00)

• 07:15 AM ET Oct 29, 2025
  

  Amarin Corp. reports Q3 EPS ($0.02) ($18.94, 0.00)

• 05:05 PM ET Oct 22, 2025
  

  Amarin Corp. appoints David Keenan as EVP, COO, effective 17-Oct-25 - 8-K ($19.62, 0.00)

• 08:44 AM ET Oct 14, 2025
  

  HLS Therapeutics and Amarin Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress

• 09:53 AM ET Oct 06, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (239 total)

• 02:04 PM ET Aug 31, 2025
  

  Amarin Corp. highlights data on EPA at ESC 2025 ($15.04, 0.00)

• 08:55 AM ET Aug 30, 2025
  

  Amarin Corp. highlights three sub-analyses from the REDUCE-IT trial describing the impact of VASCEPA/VAZKEPA ($15.04, 0.00)

• 07:14 AM ET Jul 30, 2025
  

  Amarin Corp. reports Q2 EPS ($0.03) ($14.65, 0.00)